Takeda Raises Guidance On Divestments, Improved Velcade Outlook
Executive Summary
Takeda raises its guidance for both revenue growth and core profit after its first full fiscal quarter since acquiring Shire, citing delays in US generic competition and divestments. There are as yet no clear signs of what else may be sold off however.
You may also be interested in...
Ex Shire CEO Ornskov Resurfaces To Lead Skin Group Galderma
A group of investors has bought Nestlé Skin Health, renamed it Galderma to capitalize on its legacy in dermatology and put M&A veteran, former Shire CEO Flemming Ornskov, at its helm.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.